Quantcast
The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:An Ex-TCW Exec Compares Gundlach to Cancer Not Rated 0.0 Email Routing List Email & Route  Print Print
Thursday, September 01, 2011

An Ex-TCW Exec Compares Gundlach to Cancer

News summary by MFWire's editors

Trust Company of the West's (TCW) case against Jeff Gundlach and three of his DoubleLine colleagues now rests. Yesterday TCW called its last witness, ex-TCW president Bill Sonneborn, in its legal battle with its former chief investment officer, and DoubleLine's attorneys began calling their witnesses for their cross-claim (the California term for counter-suit).

To read the rest of the story of the fight between Gundlach and TCW, click here.

Bloomberg, the Los Angeles Times, Reuters all reported on yesterday's testimony.

Sonneborn, now head of KKR Asset Management, testified that he told TCW CEO Marc Stern in August 2009 to fire Gundlach, describing Gundlach as "close to the point of becoming a disease or a cancer at the company."

Then yesterday afternoon, DoubleLine's attorneys started calling their witnesses. In a videotaped deposition, TCW chairman and founder Robert Day called Gundlach "unstable" but important because of his "tremendous track record."

DoubleLine attorney Brad Brian said he plans to call his final witness next Wednesday. 

Edited by: Neil Anderson, Managing Editor


Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE

0.0
 Do You Recommend This Story?



GO TO: MFWire
Return to Top
 News Archives
2019: Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Raw XML
Add to My Yahoo!
follow us in feedly




©All rights reserved to InvestmentWires, Inc. 1997-2019
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use